Viridian Therapeutics Inc.

7 trials 1 recruiting Commercial sponsor

Filter these 7 trials by condition, phase, country and more.

Open in Search →

7 Registered trials

1 Recruiting

6 Completed trials

8 Countries active

3 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase III: 6 Phase II/III: 1

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Endocrine ophthalmopathy 6

Top IMPs

VRDN-001 4 VRDN-003 3 SODIUM CHLORIDE 1

All trials

7 total

An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Active Thyroid Eye Disease (TED) Recruiting

2024-514972-42-00 Phase III 5 countries VRDN-003
A Safety, and Tolerability Study of VRDN-003 in Participants with Thyroid Eye Disease (TED) Ended

2024-519417-57-00 Phase III 4 countries VRDN-003
An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants with Chronic Thyroid Eye Disease (TED) Ended

2024-514973-23-00 Phase III 5 countries VRDN-003
A Safety and Tolerability Study of VRDN-001 in Persons with Thyroid Eye Disease (TED) Ended

2023-507563-19-00 Phase III 5 countries VRDN-001
An open-label study for participants who are non-responders at the end of treatment assessment on the VRDN-001-101 and VRDN-001-301 pivotal … Ended

2023-507350-33-00 Phase III 8 countries SODIUM CHLORIDE; VRDN-001
A Safety, Tolerability and Efficacy Study of VRDN-001 in Persons with Chronic Thyroid Eye Disease (TED) Ended

2023-507217-10-00 Phase III 6 countries VRDN-001
A multiple ascending dose (MAD) safety, tolerability and efficacy study of VRDN-001, a humanized monoclonal antibody directed against the IG… Ended

2024-512244-36-00 Phase II/III 4 countries VRDN-001

Showing 1–7 of 7 trials

← All sponsors A–Z